24/7 Market News Snapshot 08 July, 2025 – ZyVersa Therapeutics, Inc. Common Stock (NASDAQ:ZVSA)

July 8, 2025

DENVER, Colo., 08 July, 2025 (www.247marketnews.com) – (NASDAQ:ZVSA) are discussed in this article.
ZyVersa Therapeutics, Inc. (ZVSA) is experiencing a significant surge in pre-market trading, with shares currently priced at $1.184, marking a remarkable increase of 79.31% from the previous close of $0.660. This change is accompanied by an extraordinary trading volume of 15.53 million shares, indicating heightened investor interest in the company’s promising advancements in biotechnology. Such a bullish trend suggests robust market sentiment and raises expectations for sustained upward momentum, positioning ZyVersa as a potential focal point for investors keen on capitalizing on future growth prospects.

The company has also announced groundbreaking progress in addressing ultra-rare ApoCII amyloidosis through Emergency Compassionate Use of its innovative Cholesterol Efflux Mediator™, VAR 200. This approval allows a patient suffering from this severe condition, characterized by the abnormal buildup of amyloid proteins predominantly affecting renal function, to access this investigational therapy outside of conventional clinical trials. Dr. Alessia Fornoni, a prominent nephrology expert and director at a leading Drug Discovery Center, is leading this initiative. She posits that VAR 200 can mitigate lipid accumulation in the kidneys, potentially alleviating proteinuria and slowing disease progression.

The compassionate use of VAR 200 reflects ZyVersa’s dedication to enhancing patient outcomes, with ongoing efforts in a Phase 2a clinical trial for diabetic kidney disease further laying the groundwork for broader applications of this therapy. Under Dr. Fornoni’s guidance, this protocol mirrors existing clinical trials, promising valuable insights into its effects on proteinuria in patients with ApoCII amyloidosis.

Stephen C. Glover, ZyVersa’s Co-founder and CEO, underscored the significance of this compassionate use initiative, expressing optimism that VAR 200 will markedly improve the patient’s quality of life. The company remains committed to pioneering innovative treatments for renal and inflammatory diseases, with VAR 200 representing a critical step in addressing significant unmet medical needs.

Related news for (ZVSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.